Search Results

You are looking at 1 - 5 of 5 items for :

  • pharmacokinetics x
  • Public Health x
Clear All
Open access

Sofiya L. Ivanova, Dimitrichka J. Dimitrova, Metodi H. Petrichev, Liliana I. Parvanova, Georgi Sl. Kalistratov and Lubomir T. Vezenkov

.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for PC. Stuttgart, Jena, New York: Gustav Fisher; 1993. 18. Baggot DJ. The Physiological Basis of Veterinary Clinical Pharmacology. Oxford (UK): Blackwell Science Ltd; 2001. 19. Gibaldi M, Perrier D. Pharmacokinetics, Revised and Expanded. 2nd ed. Swarbrick J, editor. New York: Informa Healthcare Inc; 2007. 20. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:166-75. 21. Ivanova

Open access

Iwona Wertel, Wiesława Bednarek, Artur Czekierdowski and Jan Kotarski

target antigens for immunodiagnosis and immunotherapy in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1990;36:221-8. 41. Coliva A, Zacchetti A, Luison E, et. al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54:1200-13. 42. Rosenblum M, Shawver L, Marks J, et. al. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft

Open access

Stefka Valcheva-Kuzmanova, Antoaneta B. Georgieva, Stiliana P. Belcheva and Roman E. Tashev

References 1. Clifford MN. Chlorogenic acids and other cinnamates – Nature, occurrence and dietary burden. J Sci Food Agric. 1999;79(3):362-72. 2. Herrmann K. Occurrence and content of hydroxycinnamic and hydroxybenzoic acid compounds in foods. Critical Reviews in Food Sci Nutr. 1989;28(4):315-47. 3. Vafeiadou K, Vauzour D, Spencer JPE. Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets. 2007;7(3):211-24. 4. Janle EM, Lila MA, Grannan M, Wood L, Higgins A, Yousef GG et al. Pharmacokinetics and

Open access

Katya S. Kovacheva, Petya A. Nikolova, Valentin V. Hristov, Diana I. Pendicheva, Sotir T. Marchev, Tihomir R. Rashev, Georgi M. Golemanov, Zornica B. Kamburova, Maria N. Simeonova and Rusi G. Marev

events. JAMA. 2012;307( 14): 1482; author reply 1484-5. 6. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;(4):422-8. 7. Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307( 14): 1482-3; author reply 1484-5. 8. Lanham KJ,()estreichJH,DunnSP, Steinhubl SR. Impact of

Open access

Hülya Yaman, Gül Tiryaki- Sönmez and Kamil Gürel

., R. H. Böger, A. Galland, D. Tsikas, J. C. Frölich (1998a) L-arginine-induced vasodilation in healthy humans: pharmacokinetics-pharmacodynamic relationship. Br.J. Clin.Pharmacol. 46:489-497. Böger R. H., S. M. Böde-Boger (2001) The clinical pharmacology of L-arginine. Ann.Rev.Pharmacol.Toxicol. 41:79-99. Ceremuzynski L., T. Chamiec, K. Herbaczynska-Cedro (1997) Effect of supplemental oral arginine on exercise capacity in patients with stable angina pectoris. Am.J. Cardiol. 80: 331